Cointime

Vast Therapeutics

company

About

Vast Therapeutics is an innovative, preclinical-stage pharmaceutical company .

Highlights

Total Funding Amount
$16.20M
Funding Rounds
2
Investors
3
Employee Profiles
4

Details

Last Funding Type
Grant
Last Funding Money Raised
$1.20M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active
Also Known As
Novoclem

Vast Therapeutics develops inhalable treatments for antibiotic-resistant pathogens present in cystic fibrosis and other respiratory disease patients. The company is in the preclinical stage of developing inhalable therapeutics to treat chronic infections common to the cystic fibrosis population.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$16.20M
Vast Therapeutics has raised a total of $16.20M in funding over 2 rounds. Their latest funding was raised on Nov 8, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 8, 2022 Grant $1.20M 1 Collaboratory — Detail
Jan 15, 2019 Series A $15M 2 Shionogi — Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Vast Therapeutics is funded by 3 investors. Collaboratory and Shionogi are the most recent investors.
Investor Name Lead Investor Funding Round
Collaboratory Yes Grant
Shionogi Yes Series A
Cystic Fibrosis Foundation — Series A

Employee Profiles

Number of Employee Profiles
4
Vast Therapeutics has 4 current employee profiles, including Executive F. Neal Hunter
F. Neal Hunter
Executive
Charles M. Swoboda
Executive
John C. Oakley
Executive
Mark Schoenfisch
Executive
Cointime
Content
Company